Hemarthrosis

Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market

Retrieved on: 
Lunedì, Aprile 15, 2024
Hospitals, Pharmaceutical, Health, Cardiology, FDA, Administration, Boxed warning, Respiratory arrest, Injury, Bleeding, Risk, Factor VIII, Food, Hemarthrosis, Warning, Hyponatremia, Death, Polydipsia, Seizure, Contraindication, Patient, Diabetes insipidus, Central diabetes insipidus, Haemophilia, Coma, Pharmaceutical industry

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S. Food and Drug Administration.
  • Desmopressin Acetate for Injection is multi-indicated for patients with central diabetes insipidus, hemophilia A, and von Willebrand’s disease (Type I).
  • View the full release here: https://www.businesswire.com/news/home/20240415847399/en/
    Avenacy’s Desmopressin Acetate for Injection is available in two presentations: 4 mcg per 1 mL single-dose vials, and 40 mcg per 10 mL multiple-dose vials.
  • Avenacy will begin shipping Desmopressin Acetate for Injection to wholesale partners this week.

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Retrieved on: 
Sabato, Dicembre 10, 2022
Haemophilia A, Hemostasis, Bleeding, Protein, Disorder, Annual report, Person, FDA, DRS, Omicron, Safety, Arthropathy, Maintenance, Coagulation, Pharmacokinetics, Factor VIII, Haemophilia, ASH, Hemarthrosis, Thrombin, Doctor of Philosophy, APC, VIII, Joint, Factor IX, PWH, Research, OLE, Risk, Male, COVID-19, Volunteering, Patient, Coagulopathy, Pharmaceutical industry, Delta

The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).

Key Points: 
  • The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).
  • Yver and Baglin share the OLE data slides presented at ASH and discuss the SerpinPC registrational program within a recorded webcast now available on the Company’s website at https://investors.centessa.com/events-presentations .
  • SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.
  • Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients.